

● PRINTER RUSH ●

(PTO ASSISTANCE)

Application : <u>09/831123</u>	Examiner : <u>Cook</u>	GAU : <u>1641</u>	
From: <u>NAB</u>	Location: <u>IDC</u> FMF FDC	Date: <u>8-2-05</u>	
Tracking #: <u>05996924-6</u>		Week Date: <u>8-16-04</u>	

DOC CODE	DOC DATE	MISCELLANEOUS
<input type="checkbox"/> 1449		<input type="checkbox"/> Continuing Data
<input type="checkbox"/> IDS		<input type="checkbox"/> Foreign Priority
<input type="checkbox"/> CLM		<input type="checkbox"/> Document Legibility
<input type="checkbox"/> IIFW		<input type="checkbox"/> Fees
<input type="checkbox"/> SRFW		<input type="checkbox"/> Other
<input checked="" type="checkbox"/> DRW	<u>1-28-2004</u>	
<input type="checkbox"/> OATH		
<input type="checkbox"/> 312		
<input type="checkbox"/> SPEC		

[RUSH] MESSAGE: Attn.: Chief Draftsperson

Stamp covers part of the drawings.

Please Resolve.

Thank you,
NAB

[XRUSH] RESPONSE: CORRECTED DRAWINGS

8-11-05

INITIALS: IDE

NOTE: This form will be included as part of the official USPTO record, with the Response document coded as XRUSH.
REV 10/04

FIG. 1





FIG. 2







FIG. 4






FIG. 5A




FIG. 5B




FIG. 6

FIG. 7A




FIG. 7B





FIG. 8



- ▨ HOOH oxidized HSA containing 27.9 pmol cysteic acid/μg protein
- ▩ HOOH oxidized HSA containing 11.7 pmol cysteic acid/μg protein
- ▒ HOOH oxidized HSA containing 4.0 pmol cysteic acid/μg protein
- ▧ Unoxidized HSA

FIG. 9A




FIG. 9B





FIG. 10

Reactivity of mAB against PAoxBSA and unoxidized BSA



Vmax Points = 61

Well o F3 □ H1

Vmax 1.091 749.71

R² 0.912 0.983

Wells coated with either 1 µg of PAoxBSA or 1 µg of unoxidized BSA.

FIG. 11

Plate A - 96-well template

	1	2	3	4	5	6	7	8	9	10	11	12
A	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.1	1µg K2.F1.3	PAox K2.F1.3	OVA + K2.F1.3	GSA K2.F1.3	K2.F1.6	K2.F1.6	K2.F1.6	K2.F1.6
B	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.1	1 K2.F1.3	µg PA K2.F1.3	ox OVA K2.F1.3	K2.F1.3	K2.F1.6	K2.F1.6	K2.F1.6	K2.F1.6
C	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.3	1µg C K2.F1.3	M-OVA K2.F1.3	K2.F1.3	K2.F1.6	K2.F1.6	K2.F1.6	K2.F1.6
D	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.3	1µg K2.F1.3	OVA K2.F1.3	K2.F1.3	K2.F1.6	K2.F1.6	K2.F1.6	K2.F1.6
E	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.1	1µg K2.F1.3	OVA K2.F1.3	-oxCAP K2.F1.3	37 K2.F1.3	K2.F1.6	K2.F1.6	K2.F1.6	K2.F1.6
F	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.1	1µg K2.F1.3	OVA-u K2.F1.3	noxCA K2.F1.3	P 37 K2.F1.3	K2.F1.6	K2.F1.6	K2.F1.6	K2.F1.6
G	1 K2.A12	µg PA K2.A12	ox OV K2.A12	A K2.A12	1µg K2.A12	OVA- K2.A12	oxCAP K2.A12	37 K2.A12	K2.A12	K2.A12	K2.A12	K2.A12
H	K2.F1.1	K2.F1.1	K2.F1.1	K2.F1.1	1µg K2.F1.3	PAox K2.F1.3	OVA + K2.F1.3	CA K2.F1.3	K2.F1.6	K2.F1.6	K2.F1.6	K2.F1.6

FIG. 12A




FIG. 12B




FIG. 13




FIG. 14

ELISA of Patient Sera (1:200) on PAoxOVA in the
absence (col 1) and presence of oxOVA (col 2).
Percent Inhibition uncorrected for the blank.





FIG. 15

Bailey Renal Patient Plasma 1:200



Patient Number (#48 is a 'no plasma' blank)




FIG. 16A




FIG. 16B